This report was first published by Endpoints News. To see the original version, click here
D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS G12C into global registrational trials.
The Shanghai-based biotech plans to evaluate the drug, called elisrasib, as both a single agent and in combination regimens for several KRAS G12C-mutant cancers, according to a Wednesday release.
您已閱讀23%（452字），剩余77%（1545字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。